JPRN-UMIN000003511已完成1 期
Clinical trial of hTERT-derived peptide vaccine for hepatocellular carcinoma - A hTERT peptide vaccine for hepatocellular carcinoma
Department of Gastroenterology, Kanazawa University Hospital0 个研究点目标入组 14 人开始时间: 2010年4月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Severe complications associated with heart, kidney, lung, blood and coagulability 2)Infection of HIV 3)Past medical history of malignancy 4)Surgical treatment, chemotherapy and radiation therrapy within 4 weeks 5)Past medical history of Immunodeficiency, splenectomy and radiation of spleen 6)medical treatments with steroid or anti-histamine 7)Patients who are during lactation 8)Patients who are during pregnancy and expected pregnancy 9)Past history of organ transplantation 10)Patients who are predicted a difficulty of following clinical course 11)Patients who are judged inappropriate for clinical trial
研究者
相似试验
进行中（未招募）
1 期
Phase I/II trial for vaccine therapy with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion in patients with metastatic malignant melanomaEUCTR2008-006253-41-NOThe Norwegian Radium Hospital, Oslo University Hospital25
已完成
1 期
Phase I/II study of a novel peptide vaccination therapy, CDCA1 and KOC1, for previously treated advanced non-small-cell lung cancerpreviously treated advanced non-small-cell lung cancerJPRN-UMIN000005087Showa University School of Medicine26
已完成
不适用
Phase I clinical trial of peptide vaccine with UFT/LV for advanced or recurrent colorectal canceradvanced or recurrent colorectal cancerJPRN-UMIN000004452Tokyo Women's Medical University10
已完成
1 期
PhaseI/II clinical study of peptide vaccine against advanced or recurrent gastric cancerAdvanced or recurrent gastric cancer refractory to standard therapeutic modalityJPRN-UMIN000004389Department of Gastroenterological Surgery,Graduate School of Medicine,Osaka University30
已完成
2 期
Phase II clinical trial of peptide vaccination with HLA-A2402-restricted KIF20A and VEGFR1 epitope peptides with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancerpancreatic cancerJPRN-UMIN000004641Department of Gastroenterology Juntendo University School of Medicine40